Reuters -- Cell Therapeutics Inc said U.S. health regulators approved the facility to manufacture its experimental cancer drug currently under review, sending its shares up 14 percent before the bell.
Reuters -- Cell Therapeutics Inc said U.S. health regulators approved the facility to manufacture its experimental cancer drug currently under review, sending its shares up 14 percent before the bell.
